Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
02 Septiembre 2021 - 7:30AM
Business Wire
– Gastroenterology Investor Call to take
place on Tuesday, September 21, 2021 at 10:30 a.m. ET
– Dermatology Investor Call to take
place on Monday, September 27, 2021 at 11:00 a.m. ET
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they
will be hosting two virtual R&D Investor calls for analysts and
investors focused on the Company’s etrasimod programs. The Company
will also participate in five upcoming investor conferences
throughout September.
Virtual Investor Call Webcast Information
In addition to presentations by Arena’s senior management team,
the investor calls will feature presentations by and Q&A with
renowned key opinion leaders.
Gastroenterology Investor Call
Presenters:
- Robert Lisicki, Executive Vice President and Chief Commercial
Officer, Arena Pharmaceuticals
- William Sandborn, MD, Distinguished Professor of Medicine;
University of California San Diego
The video webcast will be broadcast live in listen-only mode
from 10:30 a.m. ET to 11:30 a.m. ET on Tuesday, September 21, 2021.
Register for the event here. An archived webcast of the call
will be available on the investor relations section of
Arena's website at www.arenapharm.com.
Dermatology Investor Call
Presenters:
- Doug Manion, MD, Executive Vice President, Head of Research and
Development, Arena Pharmaceuticals
- Jonathan Silverberg, MD, PhD, MPH, Associate Professor,
Director of Clinical Research; George Washington University School
of Medicine and Health Sciences
The video webcast will be broadcast live in listen-only mode
from 11:00 a.m. ET to 12:00 p.m. ET on Monday, September 27, 2021.
Register for the event here. An archived webcast of the call
will be available on the investor relations section of
Arena's website at www.arenapharm.com.
September Investor Conferences
Arena management will provide an overview of the Company during
investor meetings and presentations at five upcoming investor
conferences:
- Citi 2021 BioPharma Virtual Conference – September 9th
- Wells Fargo Virtual Healthcare Conference – September 10th
- H.C. Wainwright 23rd Annual Global Investment Conference –
September 13th & 14th
- Morgan Stanley Global Healthcare Conference – September
15th
- Cantor Fitzgerald Virtual Global Healthcare Conference –
September 28th & 29th
About Etrasimod
Etrasimod (APD334) is a next generation, once-daily, oral,
highly selective sphingosine 1-phosphate (S1P) receptor modulator
discovered by Arena and designed for optimized pharmacology and
engagement of S1P receptors 1, 4, and 5, which may lead to an
improved efficacy and safety profile. Etrasimod is intended to
provide systemic and local effects on specific immune cell types
and has the potential to treat multiple immune-mediated
inflammatory diseases including ulcerative colitis, Crohn’s
disease, eosinophilic esophagitis, atopic dermatitis, and alopecia
areata.
Etrasimod is an investigational compound that is not approved
for any use in any country.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose –
deliver important medicines to patients.
In a rapidly changing global market, we work with a sense of
urgency every day to understand the needs of all our stakeholders,
identify bold, sometimes disruptive, ideas to get medicines to
patients, and relentlessly execute until it's done.
We are developing a richly diversified portfolio of therapeutic
candidates targeting gastroenterology, dermatology and cardiology.
To fuel our growth, we are unlocking the value of our historical
GPCR research with a sustainable discovery engine for broad
portfolio expansion.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements may be identified by words such as
“designed for,” “may,” “lead to,” “intended,” and “potential to,”
and include, without limitation, statements about the potential
benefits of etrasimod, and Arena’s purpose, work, understanding,
ideas, and execution. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995.
Actual events or results may differ materially from Arena’s
expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not
limited to, the following: topline data may not accurately reflect
the complete results of a particular study or trial; results of
clinical trials and other studies are subject to different
interpretations and may not be predictive of future results;
clinical trials and other studies may not proceed at the time or in
the manner expected or at all; the timing and outcome of research,
development and regulatory review is uncertain, and Arena’s drug
candidates may not advance in development or be approved for
marketing; enrolling patients in Arena’s ongoing and intended
clinical trials is competitive and challenging; the duration and
severity of the coronavirus disease (COVID-19) pandemic, including
but not limited to the impact on Arena’s clinical operations, the
operations of Arena’s suppliers, partners, collaborators,
licensees, and capital markets, which in each case remains
uncertain; risks related to developing and commercializing drugs;
Arena will need additional funds to advance all of its programs;
the impact of competition; risks related to unexpected or
unfavorable new data; the risk that regulatory agencies may
interpret or weigh the importance of data differently and reach
different conclusions than Arena or others, request additional
information, have additional recommendations or change their
guidance or requirements before or after approval; satisfactory
resolution of litigation or other disagreements with others; and
risks related to the enforcement of Arena’s and third parties’
intellectual property rights. Additional factors that could cause
actual results to differ materially from those stated or implied by
Arena’s forward-looking statements are disclosed in Arena’s filings
with the Securities and Exchange Commission (SEC), including but
not limited to Arena’s Quarterly Report on Form 10-Q for the
quarter ended June 30, 2021, which was filed with the SEC on August
5, 2021. These forward-looking statements represent Arena’s
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210902005205/en/
Corporate Contacts: Patrick Malloy Arena Pharmaceuticals,
Inc. Vice President, Investor Relations & Corporate
Communications pmalloy@arenapharm.com 847.987.4878
Sara Doran Arena Pharmaceuticals, Inc. Associate Director,
Investor Relations & Corporate Communications
sdoran@arenapharm.com
Arena Pharmaceuticals (NASDAQ:ARNA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Arena Pharmaceuticals (NASDAQ:ARNA)
Gráfica de Acción Histórica
De May 2023 a May 2024